glp-1 news september 26 2025 Weight-Loss Drug Demonstration Begins July 2026 GLP-1 Shortage = Over -

Compared to DPP4 inhibitor, GLP-1RA use was associated with decreased risks of 30 outcomes, including respiratory failure, pneumonia, anemia, post-thrombotic sequelae, and bacterial infections, and increased risk of 13 outcomes, including sleep disturbances, nausea, vomiting, headaches, hypotension, sleep disturbances, and nephrolithiasis

Their pleiotropic effects, which range from anti-inflammatory, antioxidant, and metabolic regulation to neuroprotective and endothelial-stabilizing properties, are mediated through complex intracellular pathways, including the PI3K/Akt, AMPK, and NF-B signaling pathways

Injectable weight loss treatments do not all work on exactly the same receptors

If it doesnt, they offer compounded GLP-1s as a more affordable alternative

45 CCK plays a key role in regulating gallbladder function by binding to CCK receptors on the smooth muscle cells of the gallbladder wall, causing gallbladder contraction and the expulsion of concentrated bile through the cystic duct and into the common bile duct, eventually reaching the small intestine

Retatrutide goes one step further because it acts on glucagon (GCG) receptors as well, which also have a role in how hungry you feel